Rapt Therapeutics’ (RAPT) Market Perform Rating Reaffirmed at Lifesci Capital

Lifesci Capital restated their market perform rating on shares of Rapt Therapeutics (NASDAQ:RAPT) in a research note released on Tuesday morning,Benzinga reports.

Several other research firms have also weighed in on RAPT. JPMorgan Chase & Co. lifted their price objective on Rapt Therapeutics from $55.00 to $57.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 12th. Cowen cut Rapt Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. TD Cowen reiterated a “hold” rating on shares of Rapt Therapeutics in a report on Tuesday. HC Wainwright lowered Rapt Therapeutics from a “buy” rating to a “neutral” rating and set a $58.00 price target on the stock. in a research note on Tuesday. Finally, Barclays reduced their price objective on shares of Rapt Therapeutics from $58.00 to $56.00 and set an “overweight” rating for the company in a research report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $48.22.

Rapt Therapeutics Stock Up 64.0%

Shares of RAPT opened at $57.57 on Tuesday. The stock has a market cap of $1.60 billion, a PE ratio of -5.21 and a beta of 0.45. Rapt Therapeutics has a 12-month low of $5.67 and a 12-month high of $57.61. The business has a 50-day simple moving average of $33.31 and a two-hundred day simple moving average of $23.72.

Rapt Therapeutics (NASDAQ:RAPT) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.23. On average, equities research analysts expect that Rapt Therapeutics will post -2.14 EPS for the current year.

Institutional Trading of Rapt Therapeutics

Several hedge funds have recently bought and sold shares of RAPT. Velan Capital Investment Management LP acquired a new position in Rapt Therapeutics during the third quarter worth $2,063,000. Susquehanna International Group LLP lifted its position in Rapt Therapeutics by 173.4% in the 3rd quarter. Susquehanna International Group LLP now owns 45,382 shares of the company’s stock valued at $1,170,000 after acquiring an additional 28,782 shares in the last quarter. Millennium Management LLC boosted its stake in Rapt Therapeutics by 75.2% during the 3rd quarter. Millennium Management LLC now owns 39,278 shares of the company’s stock valued at $1,013,000 after purchasing an additional 16,854 shares during the last quarter. Boone Capital Management LLC bought a new stake in Rapt Therapeutics during the 3rd quarter worth approximately $20,180,000. Finally, Ameriprise Financial Inc. bought a new position in shares of Rapt Therapeutics in the third quarter valued at approximately $1,326,000. Institutional investors and hedge funds own 99.09% of the company’s stock.

Key Rapt Therapeutics News

Here are the key news stories impacting Rapt Therapeutics this week:

• Positive Sentiment: GSK agreed to acquire Rapt in a definitive deal valuing the company at about $2.2 billion (~$58.00 per share), providing a cash exit at a sizable premium to recent trading and directly causing the stock’s sharp rise. Article Title
• Positive Sentiment: Multiple outlets highlight that GSK gains a late‑stage food allergy antibody (ozureprubart) from Rapt’s pipeline — a strategic fit that supports the acquisition rationale and the deal premium. Article Title
• Positive Sentiment: Rapt’s investors and prior backers benefit: Forbion confirms this is a successful exit from its Growth Fund III, which validates the deal’s value to venture/early investors. Article Title
• Neutral Sentiment: Analysts have mostly left ratings and price targets around the announced deal price (Wells Fargo equal weight with $58 PT; Lifesci/TD Cowen hold), which implies limited near‑term upside beyond the acquisition consideration. Article Title
• Negative Sentiment: Several law firms have announced investigations or shareholder class‑action interest probing whether Rapt’s board negotiated a fair price, which could lead to litigation, procedural delays or settlement costs ahead of closing. Investors should monitor any formal complaints. Article Title
• Neutral Sentiment: Coverage pieces and buy/analysis notes (e.g., Seeking Alpha, The Motley Fool) frame Rapt as an attractive biotech target highlighting its long‑acting IgE candidate; useful context for strategic rationale but secondary to the binding deal terms. Article Title

About Rapt Therapeutics

RAPT Therapeutics, Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.

The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.